This article dives into how semaglutide may affect hypothyroidism and its related challenges
It is also essential to consider that correlation does not imply causation
Semaglutide consistently reduced the risk of MACE and its components in all subgroups (gender, age, and baseline cardiovascular risk)
This is known as hypoglycemia
Some plans require a step therapy failure (documented trial on semaglutide) before covering tirzepatide
Exploratory analysis In the semaglutide group, %WL did not significantly differ with age, ethnicity, diabetes status, sex, type of surgery, time from surgery (months), baseline meal-stimulated GLP-1 change, postoperative %WL (from date of surgery (DOS) to randomization), maximum %WL achieved after surgery or MBS response (weight regain versus suboptimal post-surgery weight loss)